Tazemetostat Withdrawl and RECITE
OncoPharm
00:00
Primary endpoint and patient population
John Bazar explains the primary endpoint (no chemo modification) and patient demographics in RECITE.
Play episode from 05:46
Transcript
John Bazar explains the primary endpoint (no chemo modification) and patient demographics in RECITE.
